Digimarc elects Salesforce EVP LaShonda Anderson-Williams to board of directors

Digimarc CORP

Board expanded from six to seven members; Anderson-Williams elected effective June 12, 2023.
She serves on Governance, Nominating, and Sustainability and Compensation and Talent Management Committees.
Initial restricted stock award of ~$200,000 vesting over three years; prorated annual award of ~$90,959.
Anderson-Williams is Global EVP and Chief Revenue Officer of Healthcare and Life Sciences at Salesforce.
She brings over 25 years of enterprise sales experience from Salesforce, Microsoft, and IBM.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

LaShonda Anderson-Williams

Director

DMRC · Digimarc CORP

Effective: 2023-06-12
Filed: June 6, 2023, 7:59 PM ET

On June 5, 2023, the Board of Directors (the “Board”) of Digimarc Corporation (the “Company”) approved an increase in the size of the Board from six to seven members and elected LaShonda Anderson-Williams to fill the resulting vacancy on the Board, effective June 12, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

LaShonda Anderson-Williams was elected as Director at Digimarc CORP.

Action: elected
Role: Director

Exact text from the filing

On June 5, 2023, the Board of Directors (the “Board”) of Digimarc Corporation (the “Company”) approved an increase in the size of the Board from six to seven members and elected LaShonda Anderson-Williams to fill the resulting vacancy on the Board, effective June 12, 2023.

View on SEC.gov

Digimarc CORP filing history →

Source: SEC EDGAR

accession 0001193125-23-161243

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.